Skip to main content

View full-text article in PMC

. 2024 Aug 31;30(2):104–119. doi: 10.6118/jmm.23015

Table 3. Effect of AP39 on follicular development in cisplatin and CIS-induced ovarian injury.

Folliculogenesis stage	Group
Folliculogenesis stage	Control	AP39	Cisplatin	Cisplatin + AP39	CIS	CIS + AP39
Primordial follicle	6.57 ± 0.78	4.14 ± 0.69^a	2.42 ± 0.97^a	3.14 ± 0.69^a	4.42 ± 0.97^a	4.00 ± 0.81^a
Developing follicle	13.57 ± 1.72	8.57 ± 1.13^a	5.71 ± 1.49^ab	7.71 ± 2.05^ab	9.17 ± 1.16^a	8.00 ± 1.73^a
Atretic follicle	0.42 ± 0.53	1.21 ± 0.75	2.14 ± 3.77^a	1.57 ± 0.53^a	1.28 ± 0.48	1.28 ± 0.48
Corpus luteum	10.42 ± 0.97	10.71 ± 1.11	10.73 ± 1.13	10.45 ± 1.15	10.57 ± 1.27	10.42 ± 0.97

Data presented as mean ± standard deviation.

CIS: chronic immobilization stress.

^aStatistically significant difference from the control group.

^bStatistically significant difference from the AP39 group.